EFFICACY OF HOMOEOPATHIC MEDICINES IN THE MANAGEMENT OF ACQUIRED HYPOTHYROIDISM IN CHILDREN

ROLE OF INDIVIDUALISED HOMOEOPATHIC MEDICINE IN THE MANAGEMENT OF PRIMARY AQUIRED HYPOTHYROIDISM IN PAEDIATRIC AGE GROUP: A SINGLE ARM PRE-POST INTERVENTIONAL STUDY - NIL

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/082097

Enrollment

Registered

2025-03-10

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E038- Other specified hypothyroidism

Interventions

Intervention1: Individualized Homoeopathic medicine: Indicated individualized homoeopathic medicine will be prescribed after the proper case taking and symptom similarities. Dose and frequency of repe

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with serum thyroid stimulating hormone (TSH) value more than 5.5 mlU/L to 100 mlU/L. 2. Patients with onset of symptoms mentioned in the Zulewski clinical score exceeding 3 months. 3. Patient with age group of 4-17 years. 4. Patients of all sexes, religions and socio-economic conditions. 5. Patients who have not taken any treatment in the last 4 weeks for hypothyroidism. 6. Patients or parents/guardians of patients who can read/ write/understand either English, Hindi or Bengali languages 7. Patient parents who are willing to give written informed consent and to participate in the study and give verbal (children aged between 7-12 years) or written assent (children aged between 12-17 years).

Exclusion criteria

Exclusion criteria: 1. Patients with congenital hypothyroidism, thyroid dysgenesis (aplasia, hypoplasia, ectopic gland). 2. Patients with central hypothyroidism. 3. Patients with thyroid malignancies. 4. Post ablative hypothyroidism 5. Cases with substance abuse or any psychiatric illness. 6. Congenital anomaly, critically ill and immune-compromised patients. 7. Children suffering from uncontrolled systemic diseases. 8. Simultaneous participation in any other clinical trial.

Design outcomes

Primary

Measure	Time frame
Serum TSH ValuesTimepoint: Measured at baseline and after 6 months of treatment	—

Secondary

Measure	Time frame
Zulewski s Clinical Score (ZCS) for hypothyroidism more than 5Timepoint: Measured at baseline and after 6 months of treatment;Modified Naranjo criteria for homoeopathyTimepoint: Measured at the end of 6 months	—

Countries

India

Contacts

Public ContactDr KALASAPAKAM VIJAY ANANTH

NATIONAL INSTITUTE OF HOMOEOPATHY, KOLKATA

vjananth74@gmail.com9748206295

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026